Dr. Aunins is the Executive Vice President of Bioprocess & Manufacturing and the Chief Technology Officer of Seres. He has more than 28 years of experience in the biotechnology industry, with a focus in bioprocess development, manufacturing and manufacturing support, and project leadership. Prior to joining Seres, he led process and product development teams at Merck Research Laboratories for Vaqta®, Varivax®, Zostavax®, ProQuad®, Rotateq®, and Gardasil®. The Vaqta and Gardasil process teams were awarded with ACS Industrial Biotechnology Awards for innovation, contribution to bioengineering, and societal impact. He is a Fellow of the American Institute for Medical and Biological Engineering, and an adjunct Full Professor at the Instituto de Tecnologia Química e Biológica (ITQB) in Oeiras, Portugal. He has authored over 50 articles and book chapters, and has chaired six international conferences in vaccines and bioprocess technology. Dr. Aunins earned his B.Sc. in chemical engineering at the University of Kansas, and his Ph.D. in chemical engineering from M.I.T. under Institute Professor Daniel I.C. Wang.
John G. Auniņš
Executive Vice President and Chief Technology Officer
Seres Therapeutics, Inc.